Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up.

Cernigliaro C, Sansa M, Vitrella G, Verde A, Bongo AS, Giuliani L, Novelli E.

Cardiology. 2010;115(1):77-86. doi: 10.1159/000253854. Epub 2009 Nov 2.

PMID:
19887796
2.

Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.

Stojkovic S, Ostojic M, Nedeljkovic M, Stankovic G, Beleslin B, Vukcevic V, Orlic D, Arandjelovic A, Kostic J, Dikic M, Tomasevic M.

Catheter Cardiovasc Interv. 2010 Feb 15;75(3):317-25. doi: 10.1002/ccd.22301.

PMID:
20049961
3.

Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.

Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G; ORAR II Investigators.

J Am Coll Cardiol. 2006 Apr 18;47(8):1522-9. Epub 2006 Mar 29.

4.

Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.

Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J; Oral Rapamune to Inhibit Restenosis study.

J Am Coll Cardiol. 2004 Oct 6;44(7):1386-92.

5.

Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.

Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schömig A; OSIRIS Investigators.

Circulation. 2004 Aug 17;110(7):790-5. Epub 2004 Aug 9.

PMID:
15302787
6.

Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(12):1-97. Epub 2006 Apr 1.

7.

Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G.

J Am Coll Cardiol. 2006 Dec 19;48(12):2423-31. Epub 2006 Nov 28.

8.

Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis.

Feres F, Muñoz JS, Abizaid A, Albertal M, Mintz GS, Staico R, Centemero M, Mattos LA, Maldonado G, Tanajura LF, Chaves A, Pinto I, Abizaid AS, Seixas AC, Vaz VD, Sousa A, Sousa JE.

Am J Cardiol. 2005 Dec 15;96(12):1656-62. Epub 2005 Oct 21.

PMID:
16360353
9.

Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions.

Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG.

Circulation. 2006 Aug 29;114(9):921-8. Epub 2006 Aug 14.

PMID:
16908768
10.

Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).

Rodríguez AE, Rodríguez Alemparte M, Vigo CF, Fernández Pereira C, Llauradó C, Vetcher D, Pocovi A, Ambrose J.

Heart. 2005 Nov;91(11):1433-7. Epub 2005 Mar 17.

11.

Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.

Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ.

Circulation. 2004 May 11;109(18):2168-71. Epub 2004 May 3.

PMID:
15123533
12.

Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study.

Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Feres F, Staico R, Centemero M, Tanajura LF, Abizaid AC, Rodrigues A, Paes A, Mintz GS, Sousa JE.

Catheter Cardiovasc Interv. 2005 Dec;66(4):535-40.

PMID:
16283682
13.

The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound.

Serruys PW, Foley DP, Pieper M, Kleijne JA, de Feyter PJ; TRAPIST investigators.

Eur Heart J. 2001 Oct;22(20):1938-47. Erratum in: Eur Heart J 2002 Jul;23(13):1066.

PMID:
11601838
14.

Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.

Maresta A, Balducelli M, Latini R, Bernardi G, Moccetti T, Sosa C, Barlera S, Varani E, Ribeiro da Silva EE, Monici Preti A, Maggioni AP; STARC II Investigators.

Catheter Cardiovasc Interv. 2005 Mar;64(3):375-82.

PMID:
15736248
15.

Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.

Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Rodriguez Granillo AM, Rodriguez-Granillo GA, Russo-Felssen M, Kukreja N, Antoniucci D, Palacios IF, Serruys PW; ORAR III Investigators.

EuroIntervention. 2009 Jun;5(2):255-64.

PMID:
20449934
16.

A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.

Liu HB, Xu B, Qiao SB, Yang YJ, Ma WH, Qin XW, Yao M, Wu YJ, Yuan JQ, Chen J, You SJ, Dai J, Xia R, Li JJ, Chen JL, Gao RL.

Chin Med J (Engl). 2007 Apr 5;120(7):574-7.

PMID:
17442205
17.

Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.

Popma JJ, Leon MB, Moses JW, Holmes DR Jr, Cox N, Fitzpatrick M, Douglas J, Lambert C, Mooney M, Yakubov S, Kuntz RE; SIRIUS Investigators.

Circulation. 2004 Dec 21;110(25):3773-80. Epub 2004 Dec 13.

PMID:
15596568
18.

Effect of sirolimus-eluting stent in diabetic patients with small coronary arteries (a SES-SMART substudy).

Ortolani P, Ardissino D, Cavallini C, Bramucci E, Indolfi C, Aquilina M, Marzocchi A.

Am J Cardiol. 2005 Nov 15;96(10):1393-8. Epub 2005 Sep 27.

PMID:
16275185
19.

Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.

Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA; SISR Investigators.

JAMA. 2006 Mar 15;295(11):1264-73. Epub 2006 Mar 12.

PMID:
16531619

Supplemental Content

Support Center